FGFR1 Overexpression Identified as a Key Resistance Mechanism to CDK4/6 Inhibitors in ER+ Breast Cancer
A recent study has uncovered that overexpression of FGFR1 in ER+ breast cancer cells can lead to resistance against CDK4/6 inhibitors, a common treatment strategy. This resistance mechanism was identified through a comprehensive ORF kinome screen, highlighting the potential for FGFR inhibitors to restore sensitivity to these treatments.